ACCELERATE DIAGNOSTICS, INC. Financials Accelerate Diagnostics, Inc.
Equities
AXDX
US00430H2013
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9301 USD | -1.61% |
|
+8.28% | -76.27% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 923.5 | 432.3 | 363.6 | 69.96 | 57.04 | 20.15 | - |
| Enterprise Value (EV) 1 | 945.1 | 510.4 | 408.1 | 69.96 | 57.04 | 20.15 | 20.15 |
| P/E ratio | -10.9 x | -5.41 x | -4.14 x | -0.93 x | -0.79 x | -0.41 x | -0.48 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 99.3 x | 38.7 x | 30.9 x | 5.49 x | 4.73 x | 1.66 x | 1.39 x |
| EV / Revenue | 99.3 x | 38.7 x | 30.9 x | 5.49 x | 4.73 x | 1.66 x | 1.39 x |
| EV / EBITDA | -13,149,836 x | -7,121,314 x | -8,557,434 x | - | - | - | - |
| EV / FCF | -14,180,638 x | -8,352,367 x | -7,587,701 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - | - |
| Price to Book | -125 x | -6.95 x | -10.1 x | - | - | - | - |
| Nbr of stocks (in thousands) | 5,464 | 5,703 | 6,966 | 9,910 | 14,551 | 21,664 | - |
| Reference price 2 | 169.0 | 75.80 | 52.20 | 7.060 | 3.920 | 0.9301 | 0.9301 |
| Announcement Date | 2/27/20 | 2/23/21 | 3/8/22 | 3/29/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.297 | 11.16 | 11.78 | 12.75 | 12.06 | 12.17 | 14.48 |
| EBITDA | -70.23 | -60.7 | -42.5 | - | - | - | - |
| EBIT 1 | -72.83 | -63.7 | -71.56 | -62.8 | -54.03 | -37.36 | -32.58 |
| Operating Margin | -783.38% | -570.53% | -607.37% | -492.51% | -448.03% | -307% | -224.98% |
| Earnings before Tax (EBT) 1 | -84.42 | -78.2 | -77.66 | -62.57 | -60.77 | -49 | -44.22 |
| Net income 1 | -84.3 | -78.21 | -77.7 | -62.49 | -61.62 | -49 | -44.22 |
| Net margin | -906.8% | -700.47% | -659.5% | -490.06% | -510.97% | -402.65% | -305.37% |
| EPS 2 | -15.50 | -14.00 | -12.60 | -7.600 | -4.940 | -2.270 | -1.940 |
| Free Cash Flow | -65.12 | -51.76 | -47.93 | - | - | - | - |
| FCF margin | -700.48% | -463.56% | -406.77% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/23/21 | 3/8/22 | 3/29/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.122 | 3.343 | 2.958 | 3.861 | 2.96 | 2.972 | 2.812 | 2.921 | 3.299 | 3.027 | 3 | 3 | 3 | 3.3 | 3.4 |
| EBITDA | -10.36 | -11.28 | - | - | - | - | -14.7 | -10.13 | -12.65 | - | - | - | - | - | - |
| EBIT | -14.53 | -19.41 | -15.9 | -17.99 | -14.77 | -14.15 | -16.06 | -12.58 | -13.47 | - | - | - | - | - | - |
| Operating Margin | -465.47% | -580.68% | -537.36% | -465.92% | -498.99% | -476.14% | -571.19% | -430.85% | -408.18% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -8.986 | -22.76 | -14.18 | -17.8 | -15.7 | -14.88 | -16.8 | -25.82 | 1.041 | - | - | - | - | - | - |
| Net income | -8.986 | -22.8 | -14.18 | -17.8 | -15.7 | -14.8 | -16.8 | -25.98 | 0.91 | - | - | - | - | - | - |
| Net margin | -287.83% | -682.11% | -479.55% | -461.1% | -530.57% | -497.98% | -597.26% | -889.42% | 27.58% | - | - | - | - | - | - |
| EPS 2 | -1.500 | -3.400 | -2.100 | -2.300 | -1.800 | -1.400 | -1.700 | -2.360 | 0.0600 | -0.8100 | -0.7200 | -0.5600 | -0.5100 | -0.5000 | -0.4900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/8/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/29/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | 21.6 | 78.2 | 44.4 | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.3075 x | -1.287 x | -1.046 x | - | - | - | - |
| Free Cash Flow | -65.1 | -51.8 | -47.9 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -52.7% | -68.6% | -88.1% | - | - | - | - |
| Assets 1 | 159.9 | 113.9 | 88.24 | - | - | - | - |
| Book Value Per Share | -1.350 | -10.90 | -5.180 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 0.33 | 1.36 | 0.6 | - | - | - | - |
| Capex / Sales | 3.55% | 12.2% | 5.12% | - | - | - | - |
| Announcement Date | 2/27/20 | 2/23/21 | 3/8/22 | 3/29/23 | 3/28/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9301
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -76.27% | 20.15M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- AXDX Stock
- Financials Accelerate Diagnostics, Inc.
